Respirology最新文献

筛选
英文 中文
Leading Women in Respiratory Clinical Sciences: Letter From Japan.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-18 DOI: 10.1111/resp.70033
Minako Imado, Michiko Morimoto
{"title":"Leading Women in Respiratory Clinical Sciences: Letter From Japan.","authors":"Minako Imado, Michiko Morimoto","doi":"10.1111/resp.70033","DOIUrl":"https://doi.org/10.1111/resp.70033","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking Towards More Comprehensive Management of Interstitial Lung Disease.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-18 DOI: 10.1111/resp.70015
Takuro Sakagami
{"title":"Looking Towards More Comprehensive Management of Interstitial Lung Disease.","authors":"Takuro Sakagami","doi":"10.1111/resp.70015","DOIUrl":"https://doi.org/10.1111/resp.70015","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative Assessment of Systemic Sclerosis-Related Interstitial Lung Disease via 3D-Imaging.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-17 DOI: 10.1111/resp.70024
Hiromasa Nakayasu, Yuzo Suzuki, Masato Kono, Dai Hashimoto, Shinpei Kato, Koshi Yokomura, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui, Takafumi Suda
{"title":"Quantitative Assessment of Systemic Sclerosis-Related Interstitial Lung Disease via 3D-Imaging.","authors":"Hiromasa Nakayasu, Yuzo Suzuki, Masato Kono, Dai Hashimoto, Shinpei Kato, Koshi Yokomura, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui, Takafumi Suda","doi":"10.1111/resp.70024","DOIUrl":"https://doi.org/10.1111/resp.70024","url":null,"abstract":"<p><strong>Background and objective: </strong>Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). The disease course of SSc-related ILD (SSc-ILD) is heterogeneous, and several risk-based models have been developed. This study aimed to quantitatively measure volume loss and disease extent and subsequently evaluate their associations with the development of end-stage lung disease (ESLD).</p><p><strong>Methods: </strong>Lung volume (LV) and disease extent were retrospectively and quantitatively evaluated in two cohorts (exploratory: n = 70; validation: n = 42) using high-resolution computed tomography at the time of SSc-ILD diagnosis, compared to controls (n = 70). LV was quantitatively measured using three-dimensional imaging (3D-image) and standardised by predicted forced vital capacity (standardised LV). The ratio of the normally attenuated LV (range, -950 to -750 Hounsfield units) to the whole-LV (NL%) was also measured using 3D-image. The associations of these variables with ESLD were evaluated.</p><p><strong>Results: </strong>Volume loss and normal lung area loss were noted in patients with SSc-ILD compared with controls, especially in the lower lobes. Meanwhile, extended ILD lesions without volume reduction were observed in the upper lobes. Both decreased standardised LV and NL% were associated with ESLD development, and age and NL% were significant risk factors for ESLD independent of pulmonary function test parameters and standardised LV. A composite model consisting of age and NL% successfully stratified patients with SSc-ILD based on the risk of ESLD.</p><p><strong>Conclusion: </strong>3D-image may be a useful technique for assessing disease severity and predicting the risk for ESLD in patients with SSc-ILD.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Case for Case Finding Is Getting Stronger.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-16 DOI: 10.1111/resp.70022
Christine Jenkins
{"title":"The Case for Case Finding Is Getting Stronger.","authors":"Christine Jenkins","doi":"10.1111/resp.70022","DOIUrl":"https://doi.org/10.1111/resp.70022","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for Causal Inference Studies.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-16 DOI: 10.1111/resp.70018
Rachel E Foong, Don Vicendese
{"title":"Considerations for Causal Inference Studies.","authors":"Rachel E Foong, Don Vicendese","doi":"10.1111/resp.70018","DOIUrl":"https://doi.org/10.1111/resp.70018","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comprehensive Review of Interstitial Lung Abnormalities.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-16 DOI: 10.1111/resp.70026
Yuben Moodley, John A Mackintosh
{"title":"A Comprehensive Review of Interstitial Lung Abnormalities.","authors":"Yuben Moodley, John A Mackintosh","doi":"10.1111/resp.70026","DOIUrl":"https://doi.org/10.1111/resp.70026","url":null,"abstract":"<p><p>Interstitial lung abnormalities (ILAs) represent radiological entities that comprise changes compatible with an interstitial process, occurring in individuals not suspected to have interstitial lung disease (ILD). The prevalence of ILAs ranges from 2.5% to 16.7% in lung cancer screening and population-based cohorts. ILAs have consistently been associated with mortality. Risk factors include older age, smoking, and genetic polymorphisms such as MUC5B. Progression of ILAs occurs in 20%-76% of cases over 2-6 years of follow-up. The clinical approach to ILAs involves risk stratification based on radiological features, extent of involvement, and associated clinical and physiological findings. ILAs pose a significant challenge in distinguishing inconsequential radiological findings from early ILD. This review summarises the current understanding of ILAs, including prevalence, risk factors, progression, associated biomarkers, and clinical management strategies.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations From the Medical Education Editor.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-16 DOI: 10.1111/resp.70023
Mark Lavercombe
{"title":"Recommendations From the Medical Education Editor.","authors":"Mark Lavercombe","doi":"10.1111/resp.70023","DOIUrl":"https://doi.org/10.1111/resp.70023","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tackling a Lifetime of Risk for OSA.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-12 DOI: 10.1111/resp.70025
Neeraj Mukesh Shah, Eui-Sik Suh
{"title":"Tackling a Lifetime of Risk for OSA.","authors":"Neeraj Mukesh Shah, Eui-Sik Suh","doi":"10.1111/resp.70025","DOIUrl":"https://doi.org/10.1111/resp.70025","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatable Trait Guided Asthma Management: A Feasibility Study.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-12 DOI: 10.1111/resp.70016
James Fingleton, Rob McLachlan, Jenny Sparks, Richard Beasley, Alvar Agustí, Peter G Gibson, Ian D Pavord, Jo Hardy, Mark Weatherall, Allie Eathorne, Vanessa M McDonald
{"title":"Treatable Trait Guided Asthma Management: A Feasibility Study.","authors":"James Fingleton, Rob McLachlan, Jenny Sparks, Richard Beasley, Alvar Agustí, Peter G Gibson, Ian D Pavord, Jo Hardy, Mark Weatherall, Allie Eathorne, Vanessa M McDonald","doi":"10.1111/resp.70016","DOIUrl":"https://doi.org/10.1111/resp.70016","url":null,"abstract":"<p><strong>Background and objectives: </strong>Treatable trait-based personalised medicine improves outcomes in severe asthma clinics. We assessed the feasibility of a randomised controlled trial (RCT) of protocolised treatable trait-guided asthma management in patients not under a severe asthma clinic.</p><p><strong>Methods: </strong>Ten week single-group cohort study. Participants had a doctor's diagnosis of asthma, Asthma Control Questionnaire-5 (ACQ-5) score > 1, and ≥ 1 exacerbation in the last year.</p><p><strong>Intervention: </strong>biomarker-guided asthma medication according to a protocolised algorithm, targeting traits of type-2 inflammation and airflow obstruction. Feasibility outcomes: recruitment rates, acceptability of intervention, willingness to enrol in an RCT, need for 'extended' trait assessment after 10 weeks, and estimation of trait prevalence.</p><p><strong>Results: </strong>Recruitment ceased with 29/50 participants after 14 months due to difficulties associated with COVID-19. Recruitment rate: 29/118 (25%) of those invited to participate (95% CI 17 to 33). 24/26 (92%) participants found the intervention acceptable and were willing to participate in a future study. After 10 weeks, 65% remained not well controlled (ACQ-5 > 1) and would have required the 'extended' assessment. Participants had a mean (SD) 4.8 (2.3) of 13 traits assessed. ACQ-5 improved during the study by -1.0 (0.3 to 1.8) units, and post-bronchodilator airflow limitation reduced from 59% of participants to 35%. 12/29 (41%) participants received continuous oral corticosteroids at some point during the study.</p><p><strong>Conclusion: </strong>Protocolised treatable trait management was acceptable to participants, associated with significant clinical benefit, and a full RCT appears feasible. Targeting type-2 inflammation and airflow obstruction was insufficient to control asthma in the majority of patients, despite marked systemic corticosteroid exposure.</p><p><strong>Trial registration: </strong>ACTRN12620000935932.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo-Controlled 6-Minute Walk Test Study.
IF 6.6 2区 医学
Respirology Pub Date : 2025-03-11 DOI: 10.1111/resp.70020
Giuseppina Ciarleglio, Paolo Cameli, David Bennett, Behar Cekorja, Paola Rottoli, Elisabetta A Renzoni, Piersante Sestini, Elena Bargagli
{"title":"Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo-Controlled 6-Minute Walk Test Study.","authors":"Giuseppina Ciarleglio, Paolo Cameli, David Bennett, Behar Cekorja, Paola Rottoli, Elisabetta A Renzoni, Piersante Sestini, Elena Bargagli","doi":"10.1111/resp.70020","DOIUrl":"https://doi.org/10.1111/resp.70020","url":null,"abstract":"<p><strong>Background and objective: </strong>The available evidence on the effects of ambulatory oxygen on exercise impairment in patients with fibrotic interstitial lung diseases (F-ILD) is of limited quality.</p><p><strong>Methods: </strong>We conducted a randomised, double-blind, placebo-controlled crossover trial with 32 normoxaemic F-ILD patients, desaturating to ≤ 88% during a baseline 6-minute walk test (6MWT) on ambient air. After determining the oxygen flow needed to prevent desaturation, patients completed two double-blind 6MWTs with either oxygen or placebo (compressed medical air) at the same personalised flow. Objective measures included oxygen saturation, pulse rate, and distance walked. Patient-reported outcomes, assessed via visual analogue scales, included end-of-test dyspnoea, fatigue, and preferences for walking with oxygen or placebo versus each other and ambient air.</p><p><strong>Results: </strong>Ambulatory oxygen, compared to placebo, prevented desaturation, reduced tachycardia, increased walking distance by 37 m (95% CI: 10-74, p = 0.008), and lessened dyspnoea and fatigue. The mean preference score for oxygen over placebo was 2.6 (95% CI: 1.9-3.2, p < 0.0005), significantly greater than equivalence. The preference score for placebo over ambient air was -1.5 (-2.4 to 0.64, p = 0.005), significantly lower than equivalence, while the score for oxygen over ambient air was 0.4 (-0.7 to 1.5), not significantly different from equivalence.</p><p><strong>Conclusions: </strong>Our data confirm that ambulatory oxygen provides significant benefits beyond a placebo effect; although in some patients it is associated with a negative perception that may hinder treatment acceptance. This strengthens the evidence supporting current recommendations and suggests that incorporating patient preferences recorded at the time of the 6MWT into clinical discussions can aid shared decision making regarding ambulatory oxygen.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT02668029.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信